Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 9/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656182 | 0.84 | MAPT (0.45) | ALDH1A1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL4825891 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPTPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL7140847 | 0.75 | LMNA (0.59) | ALDH1A1L3MBTL1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5657604 | 0.74 | NPC1 (0.43) | ALDH1A1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL5654058 | 0.70 | CYP1A2 (0.45) | ALDH1A1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL2026375 | 0.69 | MAPT (0.51) | ALDH1A1MAPTPOLBHSD17B10KMT2A | |
| SCHEMBL5656371 | 0.69 | ALDH1A1 (0.46) | ALDH1A1MAPTPOLBHSD17B10KMT2A | |
| Methane SCHEMBL27642737 | 0.68 | MAPT (0.50) | ALDH1A1MAPTPOLBHSD17B10KMT2A | |
| SCHEMBL11353069 | 0.68 | MAPT (0.47) | ALDH1A1MAPTPOLBHSD17B10L3MBTL1 | |
| SCHEMBL8811170 | 0.67 | MAPT (0.58) | ALDH1A1MAPTPOLBHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | ALDH1A1 519/4885MAPT 3095/4885POLB 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.